Nuclear factor erythroid 2-related factor 2 (NRF2) is a crucial transcription factor involved in oxidative stress response, which controls the expression of various cytoprotective genes. Recent research has indicated that constitutively activated NRF2 can enhance patients' resistance to chemotherapy drugs, resulting in unfavorable prognosis. Therefore, the development of NRF2 inhibitors has emerged as a promising approach for overcoming drug resistance in cancer treatment. However, there are limited reports and reviews focusing on NRF2 inhibitors. This review aims to provide a comprehensive analysis of the structure and regulation of the NRF2 signaling pathway, followed by a comprehensive review of reported NRF2 inhibitors. Moreover, the current design strategies and future prospects of NRF2 inhibitors will be discussed, aiming to establish a foundation for the development of more effective NRF2 inhibitors.
Keyphrases
- oxidative stress
- transcription factor
- signaling pathway
- nuclear factor
- randomized controlled trial
- poor prognosis
- current status
- toll like receptor
- end stage renal disease
- squamous cell carcinoma
- dna methylation
- immune response
- epithelial mesenchymal transition
- long non coding rna
- drug induced
- cell proliferation
- inflammatory response
- endoplasmic reticulum stress
- pi k akt
- genome wide analysis